- Home
- PBHC vs PROK Comparison
PBHC vs PROK Comparison
Compare PBHC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBHC
- PROK
- Stock Information
- Founded
- PBHC 1859
- PROK 2015
- Country
- PBHC United States
- PROK United States
- Employees
- PBHC N/A
- PROK N/A
- Industry
- PBHC Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBHC Finance
- PROK Health Care
- Exchange
- PBHC Nasdaq
- PROK Nasdaq
- Market Cap
- PBHC 91.0M
- PROK 85.5M
- IPO Year
- PBHC N/A
- PROK N/A
- Fundamental
- Price
- PBHC $15.07
- PROK $4.74
- Analyst Decision
- PBHC
- PROK Buy
- Analyst Count
- PBHC 0
- PROK 4
- Target Price
- PBHC N/A
- PROK $5.33
- AVG Volume (30 Days)
- PBHC 4.0K
- PROK 33.1M
- Earning Date
- PBHC 07-28-2025
- PROK 08-08-2025
- Dividend Yield
- PBHC 2.65%
- PROK N/A
- EPS Growth
- PBHC N/A
- PROK N/A
- EPS
- PBHC 0.53
- PROK N/A
- Revenue
- PBHC $41,317,000.00
- PROK $306,000.00
- Revenue This Year
- PBHC N/A
- PROK $54.34
- Revenue Next Year
- PBHC N/A
- PROK N/A
- P/E Ratio
- PBHC $28.89
- PROK N/A
- Revenue Growth
- PBHC 1.46
- PROK N/A
- 52 Week Low
- PBHC $12.79
- PROK $0.46
- 52 Week High
- PBHC $19.86
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- PBHC 53.22
- PROK 92.14
- Support Level
- PBHC $14.80
- PROK $0.54
- Resistance Level
- PBHC $15.29
- PROK $7.13
- Average True Range (ATR)
- PBHC 0.17
- PROK 0.62
- MACD
- PBHC 0.04
- PROK 0.47
- Stochastic Oscillator
- PBHC 86.02
- PROK 68.59
About PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.